Department of Neurosurgery, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel; Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
J Clin Neurosci. 2014 Jul;21(7):1116-22. doi: 10.1016/j.jocn.2013.11.010. Epub 2013 Dec 7.
We assessed the frequency and severity of changes in stent configuration and location after the treatment of intracranial aneurysms, and patterns of in-stent stenosis. We retrospectively reviewed data for consecutive aneurysm patients managed with endovascular implantation of flow-diverter stents (Silk Flow Diverter [Balt Extrusion, Montmorency, France] and Pipeline Embolization Device [ev3/Coviden, Minneapolis, MN, USA]) from October 2011 to July 2012. Routine 2, 6, 9-12, and 16-20 month follow-up angiograms were compared, with a focus on changes in stent configuration and location from immediately after deployment to angiographic follow-up, and the incidence and development of in-stent stenosis. Thirty-four patients with 42 aneurysms met inclusion criteria. The Silk device was implanted in 16 patients (47%, single device in 15), the Pipeline device in 18 (53%, single device in 16). On first follow-up angiography, in-stent stenosis was observed in 38% of Silk devices and 39% of Pipeline devices. In-stent stenosis was asymptomatic in 12 of 13 patients. One woman presented with transient ischemic attacks and required stent angioplasty due to end tapering and mild, diffuse in-stent stenosis. Configuration and location changes, including stent creeping and end tapering were seen in 2/16 patients (13%) with Silk devices, and 0/18 patients with Pipeline devices. We describe stent creeping and end tapering as unusual findings with the potential for delayed clinical complications. In-stent stenosis, with a unique behavior, is a frequent angiographic finding observed after flow-diverter stent implant. The stenosis is usually asymptomatic; however, close clinical and angiographic monitoring is mandatory for individualized management.
我们评估了颅内动脉瘤血管内治疗后支架构型和位置的变化频率和严重程度,以及支架内狭窄的模式。我们回顾性分析了 2011 年 10 月至 2012 年 7 月连续接受血流导向装置(Silk Flow Diverter [Balt Extrusion,蒙莫朗西,法国] 和 Pipeline Embolization Device [ev3/Coviden,明尼苏达州明尼阿波利斯])血管内植入治疗的动脉瘤患者的数据。比较了 2、6、9-12 和 16-20 个月的常规随访血管造影,重点是支架构型和位置从植入后立即到血管造影随访的变化,以及支架内狭窄的发生率和发展情况。34 例 42 个动脉瘤符合纳入标准。16 例患者植入 Silk 装置(47%,15 例为单装置),18 例患者植入 Pipeline 装置(53%,16 例为单装置)。首次随访血管造影时,Silk 装置支架内狭窄发生率为 38%,Pipeline 装置支架内狭窄发生率为 39%。13 例支架内狭窄无症状患者中有 12 例无症状。一名女性因末端变细和轻度弥漫性支架内狭窄导致短暂性脑缺血发作,需要支架血管成形术。16 例 Silk 装置中有 2 例(13%)和 18 例 Pipeline 装置中无 0 例出现支架构型和位置改变,包括支架爬行和末端变细。我们描述了支架爬行和末端变细是一种不常见的表现,可能会导致迟发性临床并发症。支架内狭窄是血流导向支架植入后常见的血管造影表现。这种狭窄通常是无症状的;然而,需要进行密切的临床和血管造影监测,以进行个体化治疗。